[go: up one dir, main page]

WO2002000839A3 - Novispirines: peptides antimicrobiens - Google Patents

Novispirines: peptides antimicrobiens Download PDF

Info

Publication number
WO2002000839A3
WO2002000839A3 PCT/US2001/019094 US0119094W WO0200839A3 WO 2002000839 A3 WO2002000839 A3 WO 2002000839A3 US 0119094 W US0119094 W US 0119094W WO 0200839 A3 WO0200839 A3 WO 0200839A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
gram
statement
federally sponsored
sponsored research
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019094
Other languages
English (en)
Other versions
WO2002000839A2 (fr
Inventor
Robert I Lehrer
Alan J Waring
Brian F Tack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of Iowa Research Foundation UIRF
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/840,009 external-priority patent/US6492328B2/en
Application filed by University of Iowa Research Foundation UIRF, University of California Berkeley, University of California San Diego UCSD filed Critical University of Iowa Research Foundation UIRF
Priority to EP01946359A priority Critical patent/EP1359930A4/fr
Priority to CA002415236A priority patent/CA2415236A1/fr
Priority to IL15355601A priority patent/IL153556A0/xx
Priority to JP2002505955A priority patent/JP2004526663A/ja
Priority to BRPI0112035-2A priority patent/BR0112035A/pt
Priority to AU2001268421A priority patent/AU2001268421A1/en
Publication of WO2002000839A2 publication Critical patent/WO2002000839A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002000839A3 publication Critical patent/WO2002000839A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Les peptides de novispirine sont des agents antimicrobiens avec une activité efficace contre les bactéries Gram négatif. Ces peptides sont non hémolytiques, présentent une cytotoxicité in vivo réduite par rapport à d'autres peptides antimicrobiens, et ils ont été bien tolérés in vivo après une injection intraveineuse. Ces novispirines se lient aussi avec la lipopolysaccharide (LPS), propriété qui peut atténuer les symptômes associés à l'infection par la bactérie Gram négatif. On administre une composition pharmaceutique comprenant de la novispirine comme principe actif à un patient souffrant d'une infection microbienne ou prédisposé à cette infection, et plus particulièrement aux infections par la bactérie Gram négatif.
PCT/US2001/019094 2000-06-28 2001-06-13 Novispirines: peptides antimicrobiens Ceased WO2002000839A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01946359A EP1359930A4 (fr) 2000-06-28 2001-06-13 Novispirines: peptides antimicrobiens
CA002415236A CA2415236A1 (fr) 2000-06-28 2001-06-13 Novispirines: peptides antimicrobiens
IL15355601A IL153556A0 (en) 2000-06-28 2001-06-13 Novispirins: antimicrobial peptides
JP2002505955A JP2004526663A (ja) 2000-06-28 2001-06-13 ノビスピリン抗菌ペプチド
BRPI0112035-2A BR0112035A (pt) 2000-06-28 2001-06-13 peptìdeos antimicrobianos de novispirin
AU2001268421A AU2001268421A1 (en) 2000-06-28 2001-06-13 Statement as to federally sponsored research

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60685800A 2000-06-28 2000-06-28
US09/606,858 2000-06-28
US09/840,009 US6492328B2 (en) 2000-06-28 2001-04-19 Novispirins: antimicrobial peptides
US09/840,009 2001-04-19

Publications (2)

Publication Number Publication Date
WO2002000839A2 WO2002000839A2 (fr) 2002-01-03
WO2002000839A3 true WO2002000839A3 (fr) 2003-08-28

Family

ID=27085347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019094 Ceased WO2002000839A2 (fr) 2000-06-28 2001-06-13 Novispirines: peptides antimicrobiens

Country Status (7)

Country Link
EP (1) EP1359930A4 (fr)
JP (1) JP2004526663A (fr)
AU (1) AU2001268421A1 (fr)
BR (1) BR0112035A (fr)
CA (1) CA2415236A1 (fr)
IL (1) IL153556A0 (fr)
WO (1) WO2002000839A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071293B1 (en) * 1999-08-18 2006-07-04 The University Of Iowa Research Foundation Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt
ATE422894T1 (de) * 2002-03-21 2009-03-15 Cayman Chem Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
WO2005092365A2 (fr) * 2004-03-29 2005-10-06 Novozymes A/S Utilisation pharmaceutique des novispirines
US7148404B2 (en) * 2004-05-04 2006-12-12 Novozymes A/S Antimicrobial polypeptides
WO2008096814A1 (fr) * 2007-02-09 2008-08-14 Genomidea Inc. Nouveau polypeptide et agent antibactérien le renfermant en tant que principe actif
GB201115910D0 (en) 2011-09-14 2011-10-26 Univ Manchester Peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012668A1 (fr) * 1999-08-18 2001-02-22 University Of Iowa Research Foundation Peptides derives de la cathelicidine ayant une activite antimicrobienne a large spectre

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012668A1 (fr) * 1999-08-18 2001-02-22 University Of Iowa Research Foundation Peptides derives de la cathelicidine ayant une activite antimicrobienne a large spectre

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 15 May 2001 (2001-05-15), TACK ET AL.: "Ovine SMAP 29 cathelicidin derived antimicrobial peptide", XP002963608, Database accession no. (AAB70648) *
DATABASE PIR_71 [online] 28 October 1996 (1996-10-28), MAHONEY ET AL.: "Cathelin-related protein 2 precursor-sheep (fragment)", XP002963606, Database accession no. (S68411) *
FEBS LETTERS, vol. 376, 1995, pages 225 - 228 *
MAHONEY ET AL.: "Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide", FEBS LETTERS, vol. 377, 1995, pages 519 - 522, XP002963607 *

Also Published As

Publication number Publication date
IL153556A0 (en) 2003-07-06
JP2004526663A (ja) 2004-09-02
EP1359930A4 (fr) 2004-07-14
WO2002000839A2 (fr) 2002-01-03
AU2001268421A1 (en) 2002-01-08
EP1359930A2 (fr) 2003-11-12
BR0112035A (pt) 2006-02-21
CA2415236A1 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
CA2415068A1 (fr) Renforcement global de l'organisme
CA2408142A1 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
WO2001092288A3 (fr) Composes de cobalamine utilises comme agents antibiotiques et comme agents d'imagerie
EP1283050A3 (fr) Compositions thérapeutiques améliorées comprenant des protéines augmentant le pouvoir bactéricide perméabilisant
AU2002211536A1 (en) Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
WO2003010138A3 (fr) Medicaments
BG103969A (en) C-4"-substituted macrolide derivatives
WO2001082971A3 (fr) Compositions pharmaceutiques contenant un antibiotique glycopeptidique et une cyclodextrine
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
CA2360220A1 (fr) Composes a base d'oxadiazole et compositions destinees a l'apport d'agents actifs
GB9902555D0 (en) Medicament
WO2001092309A3 (fr) Defensine humaine beta 3 (hbd-3), peptide antimicrobien hautement cationique de la defensine beta
WO2002055543A3 (fr) Composes, compositions pharmaceutiques et procedes pour le traitement de bacteriemie et/ou septicemie
CA2388910A1 (fr) Activite antimicrobienne du premier groupe cationique de la lactoferrine humaine
WO2000000214A3 (fr) Preparations pharmaceutiques destinees a combattre ou a prevenir les infections superficielles provoquees par des micro-organismes
AU2003290015A1 (en) Mastitis treatment
WO2002000839A3 (fr) Novispirines: peptides antimicrobiens
WO2003009859A1 (fr) Immunotherapie pour humains
AU7792294A (en) Antibacterial composition containing multimeric alpha-lactalbumin
WO2002000208A3 (fr) Preparations de derives d'acide 3-n-formylhydroxylaminopropylphosphonique ou de derives d'acide 3-n-acetylhydroxylaminopropylphosphonique combines avec des principes actifs pharmaceutiques speciaux
WO2004033479A3 (fr) Les retrocyclines, des peptides antiviraux et antimicrobiens
WO2001070184A3 (fr) Composition contenant des monoterpenes destinee a une administration orale topique
WO2005026194A3 (fr) Peptides granulysine et leurs procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153556

Country of ref document: IL

Ref document number: 2415236

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001268421

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/2155/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018118623

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003/00374

Country of ref document: ZA

Ref document number: 200300374

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001946359

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001946359

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0112035

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2001946359

Country of ref document: EP